• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Development of pharmacodynamic tolerance to prozosin in congestive heart failure.

作者信息

Desch C E, Magorien R D, Triffon D W, Blanford M F, Unverferth D V, Leier C V

出版信息

Am J Cardiol. 1979 Nov;44(6):1178-82. doi: 10.1016/0002-9149(79)90185-1.

DOI:10.1016/0002-9149(79)90185-1
PMID:495512
Abstract

In order to determine and compare the pharmacodynamic responses to single and multiple dose prazosin therapy in cardiac failure, 14 patients with severe low-output heart failure underwent central and regional hemodynamic measurements after random placement in one of two prazosin dosing schedules. A single 5 mg oral dose of prazosin (Group A, no. = 7) significantly increased the cardiac index and stroke volume index while significantly decreasing systemic, pulmonary and pulmonary capillary wedge pressures and vascular resistances. Hepatic plasma flow and limb blood flow increased after the single dose. Striking attenuation of these hemodynamic effects occurred when the same dose was administered after 24 hours of pretreatment with oral prazosin, 2 mg every 8 hours (Group B, no. = 7). The plasma prazosin levels of the two groups, drawn 2 hours after administration, were 24.5 and 30.5 ng/ml, respectively. Repeated administration of prazosin in patients with congestive heart failure results in rapid attenuation of its beneficial central and regional hemodynamic effects. The usefulness of this vasodilator as a preload- and afterload-reducing agent in the clinical setting of chronic congestive heart failure may be limited by the development of pharmacodynamic tolerance.

摘要

相似文献

1
Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
Am J Cardiol. 1979 Nov;44(6):1178-82. doi: 10.1016/0002-9149(79)90185-1.
2
Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.
Ann Intern Med. 1981 Jul;95(1):5-13. doi: 10.7326/0003-4819-95-1-5.
3
Attenuation of prazosin effect on cardiac output in chronic heart failure.哌唑嗪对慢性心力衰竭心输出量作用的减弱
Ann Intern Med. 1979 Sep;91(3):345-9. doi: 10.7326/0003-4819-91-3-345.
4
Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure.静脉注射硝普钠与口服哌唑嗪对难治性心力衰竭的血流动力学比较效应
Am J Cardiol. 1978 May 1;41(5):925-30. doi: 10.1016/0002-9149(78)90735-x.
5
Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow.硝苯地平治疗充血性心力衰竭:对静息和运动时血流动力学及局部血流的影响。
Am Heart J. 1984 Dec;108(6):1461-8. doi: 10.1016/0002-8703(84)90693-8.
6
Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.
Cardiovasc Drugs Ther. 1988 Jan;1(5):529-34. doi: 10.1007/BF02125736.
7
Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure.充血性心力衰竭患者对慢性哌唑嗪治疗的有益血流动力学反应。
Am Heart J. 1981 May;101(5):534-40. doi: 10.1016/0002-8703(81)90218-0.
8
Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure.
Am J Cardiol. 1979 Jul;44(1):126-31. doi: 10.1016/0002-9149(79)90261-3.
9
Use of oral prazosin hydrochloride in congestive failure following acute myocardial infarction.口服盐酸哌唑嗪在急性心肌梗死后充血性心力衰竭中的应用。
Am Heart J. 1979 Oct;98(4):495-504.
10
Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.口服哌唑嗪治疗慢性充血性心力衰竭时血流动力学效应的早期显著减弱。
Am J Cardiol. 1979 Sep;44(3):540-5. doi: 10.1016/0002-9149(79)90409-0.

引用本文的文献

1
The myocardial matrix and the development and progression of ventricular remodeling.心肌基质与心室重构的发生和进展
Curr Cardiol Rep. 2000 Mar;2(2):112-9. doi: 10.1007/s11886-000-0007-4.
2
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
3
The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure.舒马唑(AR-L 115 BS)对慢性心力衰竭血流动力学的有效血浆浓度。
Br J Clin Pharmacol. 1983 Sep;16(3):313-8. doi: 10.1111/j.1365-2125.1983.tb02167.x.
4
Vasodilator therapy in chronic congestive heart failure.慢性充血性心力衰竭的血管扩张剂治疗
Drugs. 1983 Aug;26(2):148-73. doi: 10.2165/00003495-198326020-00003.
5
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.哌唑嗪最新进展。对其药理特性以及在高血压和充血性心力衰竭治疗中的应用综述。
Drugs. 1983 Apr;25(4):339-84. doi: 10.2165/00003495-198325040-00002.
6
Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.
Cardiovasc Drugs Ther. 1988 Jan;1(5):529-34. doi: 10.1007/BF02125736.
7
Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.
Clin Pharmacokinet. 1989 Oct;17(4):264-74. doi: 10.2165/00003088-198917040-00004.
8
Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.充血性心力衰竭中不使用血管紧张素转换酶抑制剂的血管扩张剂治疗——效用与局限性
Cardiovasc Drugs Ther. 1989 Jun;3(3):375-96. doi: 10.1007/BF01858109.
9
Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.氟司喹南对充血性心力衰竭患者初始血流动力学效应的持续时间及可重复性。
Cardiovasc Drugs Ther. 1990 Jun;4(3):705-12. doi: 10.1007/BF01856558.
10
The description and prediction of antihypertensive drug response: an individualised approach.抗高血压药物反应的描述与预测:一种个体化方法。
Br J Clin Pharmacol. 1991 Jun;31(6):627-34. doi: 10.1111/j.1365-2125.1991.tb05584.x.